SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm.

Colorectal liver metastases Guideline Hepatocellular carcinoma Liver tumor Microwave ablation Radiofrequency ablation

Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 23 08 2023
accepted: 07 09 2023
pubmed: 14 11 2023
medline: 14 11 2023
entrez: 13 11 2023
Statut: ppublish

Résumé

Primary hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM) represent the liver's two most common malignant neoplasms. Liver-directed therapies such as ablation have become part of multidisciplinary therapies despite a paucity of data. Therefore, an expert panel was convened to develop evidence-based recommendations regarding the use of microwave ablation (MWA) and radiofrequency ablation (RFA) for HCC or CRLM less than 5 cm in diameter in patients ineligible for other therapies. A systematic review was conducted for six key questions (KQ) regarding MWA or RFA for solitary liver tumors in patients deemed poor candidates for first-line therapy. Subject experts used the GRADE methodology to formulate evidence-based recommendations and future research recommendations. The panel addressed six KQs pertaining to MWA vs. RFA outcomes and laparoscopic vs. percutaneous MWA. The available evidence was poor quality and individual studies included both HCC and CRLM. Therefore, the six KQs were condensed into two, recognizing that these were two disparate tumor groups and this grouping was somewhat arbitrary. With this significant limitation, the panel suggested that in appropriately selected patients, either MWA or RFA can be safe and feasible. However, this recommendation must be implemented cautiously when simultaneously considering patients with two disparate tumor biologies. The limited data suggested that laparoscopic MWA of anatomically more difficult tumors has a compensatory higher morbidity profile compared to percutaneous MWA, while achieving similar overall 1-year survival. Thus, either approach can be appropriate depending on patient-specific factors (very low certainty of evidence). Given the weak evidence, these guidelines provide modest guidance regarding liver ablative therapies for HCC and CRLM. Liver ablation is just one component of a multimodal approach and its use is currently limited to a highly selected population. The quality of the existing data is very low and therefore limits the strength of the guidelines.

Sections du résumé

BACKGROUND BACKGROUND
Primary hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM) represent the liver's two most common malignant neoplasms. Liver-directed therapies such as ablation have become part of multidisciplinary therapies despite a paucity of data. Therefore, an expert panel was convened to develop evidence-based recommendations regarding the use of microwave ablation (MWA) and radiofrequency ablation (RFA) for HCC or CRLM less than 5 cm in diameter in patients ineligible for other therapies.
METHODS METHODS
A systematic review was conducted for six key questions (KQ) regarding MWA or RFA for solitary liver tumors in patients deemed poor candidates for first-line therapy. Subject experts used the GRADE methodology to formulate evidence-based recommendations and future research recommendations.
RESULTS RESULTS
The panel addressed six KQs pertaining to MWA vs. RFA outcomes and laparoscopic vs. percutaneous MWA. The available evidence was poor quality and individual studies included both HCC and CRLM. Therefore, the six KQs were condensed into two, recognizing that these were two disparate tumor groups and this grouping was somewhat arbitrary. With this significant limitation, the panel suggested that in appropriately selected patients, either MWA or RFA can be safe and feasible. However, this recommendation must be implemented cautiously when simultaneously considering patients with two disparate tumor biologies. The limited data suggested that laparoscopic MWA of anatomically more difficult tumors has a compensatory higher morbidity profile compared to percutaneous MWA, while achieving similar overall 1-year survival. Thus, either approach can be appropriate depending on patient-specific factors (very low certainty of evidence).
CONCLUSION CONCLUSIONS
Given the weak evidence, these guidelines provide modest guidance regarding liver ablative therapies for HCC and CRLM. Liver ablation is just one component of a multimodal approach and its use is currently limited to a highly selected population. The quality of the existing data is very low and therefore limits the strength of the guidelines.

Identifiants

pubmed: 37957297
doi: 10.1007/s00464-023-10468-1
pii: 10.1007/s00464-023-10468-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8991-9000

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Ferlay J, Parkin DM, Curado MP et al (2014) Cancer incidence in five continents, volumes I to X: IARC CANCERBase No. 10. http://ci5.iarc.fr . Accessed 25 Nov 2014
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
doi: 10.3322/caac.21262 pubmed: 25651787
Rich NE, Yopp AC, Singal AG, Murphy CC (2020) Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. Clin Gastroenterol Hepatol 18(242–248):e245
Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A (2020) Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 11:761–808
doi: 10.5306/wjco.v11.i10.761 pubmed: 33200074 pmcid: 7643190
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A (2020) Colorectal cancer statistics. CA Cancer J Clin 70:145–164
doi: 10.3322/caac.21601 pubmed: 32133645
Bhardwaj N, Strickland A, Ahmad F, Dennison A, Lloyd D (2010) Liver ablation techniques: a review. Surg Endosc 24:254–265
doi: 10.1007/s00464-009-0590-4 pubmed: 19554370
Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D’Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Natl Compr Canc Netw 7:350–391
doi: 10.6004/jnccn.2009.0027
Decadt B, Siriwardena AK (2004) Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol 5:550–560
doi: 10.1016/S1470-2045(04)01567-0 pubmed: 15337485
McGhana JP, Dodd GD III (2001) Radiofrequency ablation of the liver: current status. Am J Roentgenol 176:3–16
doi: 10.2214/ajr.176.1.1760003 pubmed: 11133529
Abdalla M, Collings AT, Dirks R, Onkendi E, Nelson D, Ozair A, Miraflor E, Rahman F, Whiteside J, Shah MM, Ayloo S, Abou-Setta A, Sucandy I, Kchaou A, Douglas S, Polanco P, Vreeland T, Buell J, Ansari MT, Pryor AD, Slater BJ, Awad Z, Richardson W, Alseidi A, Jeyarajah DR, Ceppa EP (2022) Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis. Surg Endosc 37(5):3340–3353. https://doi.org/10.1007/s00464-022-09815-5
doi: 10.1007/s00464-022-09815-5 pubmed: 36542137
Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Schünemann HJ (2016) GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ 353:12089
Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD, GRADE Working Group (2016) GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ 353:12016
Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G (2013) GRADE guidelines: 15 going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 66(7):726–735
doi: 10.1016/j.jclinepi.2013.02.003 pubmed: 23570745
Chen Y, Yang K, Marusic A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ES, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL, RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group (2017) A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med 166:128–132
doi: 10.7326/M16-1565 pubmed: 27893062
Rogers AT, Dirks R, Burt HA, Haggerty S, Kohn GP, Slater BJ, Walsh D, Stefanidis D, Pryor A (2021) Society of American gastrointestinal and endoscopic SURGEONS (SAGES) guidelines development: standard operating procedure. Surg Endosc 35:2417–2427
doi: 10.1007/s00464-021-08469-z pubmed: 33871718
Schünemann HJ, Brożek J, Guyatt G, Oxman AD (eds) (2013) GRADE handbook: handbook for grading quality of evidence and strength of recommendations. https://guidelinedevelopment.org/handbook . Accessed Oct 2013
An C, Li WZ, Huang ZM, Yu XL, Han YZ, Liu FY, Wu SS, Yu J, Liang P, Huang J (2021) Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. Eur Radiol 31:4764–4773
doi: 10.1007/s00330-020-07571-5 pubmed: 33399908 pmcid: 8213545
Correa-Gallego C, Fong Y, Gonen M, D’Angelica MI, Allen PJ, DeMatteo RP, Jarnagin WR, Kingham TP (2014) A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 21:4278–4283
doi: 10.1245/s10434-014-3817-0 pubmed: 24889486 pmcid: 4529120
Iida H, Aihara T, Ikuta S, Yamanaka N (2013) A comparative study of therapeutic effect between laparoscopic microwave coagulation and laparoscopic radiofrequency ablation. Hepatogastroenterology 60:662–665
pubmed: 23178517
Lee KF, Wong J, Hui JW, Cheung YS, Chong CC, Fong AK, Yu SC, Lai PB (2017) Long-Term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: a retrospective comparative study. Asian J Surg 40:301–308
doi: 10.1016/j.asjsur.2016.01.001 pubmed: 26922631
Santambrogio R, Chiang J, Barabino M, Meloni FM, Bertolini E, Melchiorre F, Opocher E (2017) Comparison of laparoscopic microwave to radiofrequency ablation of small hepatocellular carcinoma (≤3 cm). Ann Surg Oncol 24:257–263
doi: 10.1245/s10434-016-5527-2 pubmed: 27581608
Simo KA, Sereika SE, Newton KN, Gerber DA (2011) Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation: lap-MWA for HCC: safety and efficacy. J Surg Oncol 104:822–829
doi: 10.1002/jso.21933 pubmed: 21520094
Takahashi H, Kahramangil B, Kose E, Berber E (2018) A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB 20:1157–1162
doi: 10.1016/j.hpb.2018.05.012 pubmed: 29929785
Yang B, Yuwei L (2017) A comparative study of laparoscopic microwave ablation with laparoscopic radiofrequency ablation for colorectal liver metastasis. J BUON 22:667–672
pubmed: 28730772
Sakaguchi H, Seki S, Tsuji K, Teramoto K, Suzuki M, Kioka K, Isoda N, Ido K (2009) Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study. Hepatol Res 39:47–52. https://doi.org/10.1111/j.1872-034X.2008.00410.x
doi: 10.1111/j.1872-034X.2008.00410.x pubmed: 18761680
De Cobelli F, Marra P, Ratti F, Ambrosi A, Colombo M, Damascelli A, Sallemi C, Gusmini S, Salvioni M, Diana P, Cipriani F, Venturini M, Aldrighetti L, Del Maschio A (2017) Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions: new advances in interventional oncology: state of the art. Med Oncol 34:49
doi: 10.1007/s12032-017-0903-8 pubmed: 28220346
Della Corte A, Ratti F, Monfardini L, Marra P, Gusmini S, Salvioni M, Venturini M, Cipriani F, Aldrighetti L, De Cobelli F (2020) Comparison between percutaneous and laparoscopic microwave ablation of hepatocellular carcinoma. Int J Hyperthermia 37:542–548
doi: 10.1080/02656736.2020.1769869 pubmed: 32469252

Auteurs

Eugene P Ceppa (EP)

Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr, EH541, Indianapolis, IN, 46202, USA. eceppa@iu.edu.

Amelia T Collings (AT)

Hiram C. Polk, Jr. Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.

Moustafa Abdalla (M)

Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Edwin Onkendi (E)

Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Daniel W Nelson (DW)

Department of Surgery, William Beaumont Army Medical Center, El Paso, TX, USA.

Ahmad Ozair (A)

King George's Medical University, Lucknow, India.

Emily Miraflor (E)

UCSF East Bay Department of Surgery, UCSF, Oakland, CA, USA.

Faique Rahman (F)

Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India.

Jake Whiteside (J)

Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr, EH541, Indianapolis, IN, 46202, USA.

Mihir M Shah (MM)

Division of Surgical Oncology, Department of Surgery, Emory University Winship Cancer Institute, Atlanta, GA, USA.

Subhashini Ayloo (S)

Department of Surgery, Brown University, Providence, RI, USA.

Rebecca Dirks (R)

Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr, EH541, Indianapolis, IN, 46202, USA.

Sunjay S Kumar (SS)

Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

Mohammed T Ansari (MT)

School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Iswanto Sucandy (I)

Digestive Health Institute, AdventHealth, Tampa, FL, USA.

Kchaou Ali (K)

Department of Surgery A, Sfax Medical School, Sfax, Tunisia.

Sam Douglas (S)

Department of Surgery, Naval Medical Center Portsmouth, Portsmouth, VA, USA.

Patricio M Polanco (PM)

Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Timothy J Vreeland (TJ)

Department of Surgery, Brooke Army Medical Center, San Antonio, TX, USA.

Joseph Buell (J)

Department of Surgery, Mission Health Care System, Asheville, NC, USA.

Ahmed M Abou-Setta (AM)

University of Manibota, Winnepeg, Canada.

Ziad Awad (Z)

Department of Surgery, University of Florida, Jacksonville, FL, USA.

Choon Hyuck Kwon (CH)

Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.

John B Martinie (JB)

Department of Surgery, Atrium Health, Charlotte, NC, USA.

Fabio Sbrana (F)

Department of Surgery, Chicago Medical School, Rosalind Franklin University, Chicago, IL, USA.

Aurora Pryor (A)

Department of Surgery, Long Island Jewish Medical Center, Northwell Health, Great Neck, NY, USA.

Bethany J Slater (BJ)

Department of Surgery, University of Chicago, Chicago, IL, USA.

William Richardson (W)

Department of Surgery, Ochsner Clinic, Jefferson, LA, USA.

Rohan Jeyarajah (R)

TCU/UNTHSC School of Medicine, Fort Worth, TX, USA.

Adnan Alseidi (A)

Department of Surgery, University of California, San Francisco, CA, USA.

Classifications MeSH